Erasmus School of Health Policy & Management
Endowed professor | Health Technology Assessment (HTA)
- retel@eshpm.eur.nl
- Location
- Burg. Oudlaan 50, Rotterdam
More information
Work
- Zakile A. Mfumbilwa, Martijn J.H.G. Simons, Bram Ramaekers, Valesca P. Retèl, Joanne M. Mankor, Harry J.M. Groen, Joachim G.J.V. Aerts, Manuela Joore, Janneke A. Wilschut & Veerle M.H. Coupé (2024) - Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy - PharmacoEconomics, 42 (4), 419-434 - doi: 10.1007/s40273-023-01344-w - [link]
- Michael Schlander, Wim van Harten, Valesca P. Retèl, Phu Duy Pham, Julie M. Vancoppenolle, Jasper Ubels, Olaya Seoane López, Camila Quirland, Felipe Maza, Eline Aas, Bernd Crusius, Agustín Escobedo, Nora Franzen, Jeanette Fuentes-Cid, Diego Hernandez, Karla Hernandez-Villafuerte, Iva Kirac, Artus Paty, Thierry Philip, Sigbjørn Smeland, Richard Sullivan, Elena Vanni, Sinisa Varga, Thomas Vermeulin & Rachel D. Eckford (2024) - The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions - The Lancet Oncology, 25 (4), e152-e163 - doi: 10.1016/S1470-2045(23)00636-8 - [link]
- Renske M.T. Ten Ham, Maartje W. Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Bastiaan Nuijen, Cynthia Nijenhuis, Melanie Lindenberg, Troels Holz Borch, Tine Monberg, Marco Donia, Inge Marie Svane, Wim van Harten, John Haanen & Valesca P. Retel (2024) - Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial - Journal for ImmunoTherapy of Cancer, 12 (3) - doi: 10.1136/jitc-2023-008372 - [link]
- Julie M. Vancoppenolle, Nora Franzen, Simone N. Koole, Valesca P. Retèl & Wim H. van Harten (2024) - Differences in time to patient access to innovative cancer medicines in six European countries - International Journal of Cancer, 154 (5), 886-894 - doi: 10.1002/ijc.34753 - [link]
- Ruby M. van Stein, Florine J. Hendriks, Valesca P. Retèl, Cor D. de Kroon, Christianne A.R. Lok, Gabe S. Sonke, Kelly M. de Ligt & Willemien J. van Driel (2023) - Health state utility and health-related quality of life measures in patients with advanced ovarian cancer - Gynecologic Oncology Reports, 50 - doi: 10.1016/j.gore.2023.101293 - [link]
- A. Klaassen-Dekker, C. H.C. Drossaert, M. C. Van Maaren, A. E. Van Leeuwen-Stok, V. P. Retel, J. C. Korevaar & S. Siesling (2023) - Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design - BMC Cancer, 23 (1) - doi: 10.1186/s12885-023-11504-y - [link]
- Joost G.E. Verbeek, Karen van der Sluis, Marieke A. Vollebergh, Johanna W. van Sandick, Wim H. van Harten & Valesca P. Retèl (2023) - Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis - PharmacoEconomics - Open, 8 (1), 119-131 - doi: 10.1007/s41669-023-00454-7 - [link]
- Michiel van de Ven, Erik Koffijberg, Valesca Retel, Wim Van Harten & Maarten IJzerman (2023) - Dynamic Simulation Modeling to Analyze the Impact of Whole Genome Sequencing National Implementation Scenarios in Lung cancer on Time - doi: 10.1101/2023.11.10.23298371
- M. D. Egeler, E. Boomstra, M. W. Rohaan, N. M.J. Van den Heuvel, I. Fraterman, M. Delfos, L. V. van de Poll-Franse, T. H. Borch, I. M. Svane, J. B.A.G. Haanen, V. P. Retèl & A. H. Boekhout (2023) - “One more chance to survive”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care - Journal of Cancer Survivorship - doi: 10.1007/s11764-023-01452-8 - [link]
- Julie M. Vancoppenolle, Simone N. Koole, James F. O'Mahony, Nora Franzen, Jacobus A. Burgers, Valesca P. Retèl & Willem H. van Harten (2023) - Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe - Drug Discovery Today, 28 (8), 1-5 - doi: 10.1016/j.drudis.2023.103620 - [link]
Health Economics Organisation European Cancer Inst
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- BRUSSEL
- Description
- Coordinator werkgroep
KWF
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- ROTTERDAM
- Description
- Lid beoordelingscommissie
NKI-AVL Amsterdam
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- AMSTERDAM
- Description
- Hoofd afdeling Health Technology Assessment
ZonMW
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- DEN HAAG
- Description
- Lid beoordelingscommissie
Master Thesis Eu-HEM
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4560M
